Corvus Pharmaceuticals (CRVS) Payables (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Payables of $4.7 million for Q1 2026, up 259.1% year-over-year from $1.3 million in Q1 2025, and up 88.56% quarter-over-quarter from $2.5 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Payables (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Payables history runs 12 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- In Q1 2026, Payables rose 259.1% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (up 259.1% YoY), while the FY2025 annual figure was $2.5 million, down 3.52% from the prior year.
- Payables for Q1 2026 stood at $4.7 million, up from $2.5 million in the prior quarter.
- The five-year high for Payables was $4.7 million in Q1 2026, with the low at $730000.0 in Q2 2025.
- The 5-year median for Payables is $1.9 million (2024), against an average of $2.1 million.
- The sharpest annual moves came in 2023 and 2026: Payables slumped 66.78% in 2023, then surged 259.1% in 2026.
- Corvus Pharmaceuticals' Payables stood at $2.0 million in 2022, then fell by 22.82% to $1.5 million in 2023, then jumped by 69.31% to $2.6 million in 2024, then fell by 3.52% to $2.5 million in 2025, then soared by 88.56% to $4.7 million in 2026.
- Business Quant data shows CRVS's Payables at $4.7 million in Q1 2026, $2.5 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 4.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.05 Mn |
| Mar 31, 2026 | 4.70 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 730,000.00 |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.98 Mn |
| Sep 30, 2022 | 4.23 Mn |
| Jun 30, 2022 | 2.65 Mn |
| Mar 31, 2022 | 2.19 Mn |
| Dec 31, 2021 | 1.57 Mn |
| Sep 30, 2021 | 2.33 Mn |